ReviewFrontiers in immunology2025
Biochemical markers and emerging therapies for intestinal manifestation of graft-versus-host disease.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graft-versus-host disease (GVHD) remains a potentially fatal complication of allogeneic hematopoietic stem cell transplantation (alloHCT). Gastrointestinal involvement, whether in acute or chronic GVHD, is associated with a poorer prognosis and poses significant diagnostic and therapeutic challenges. Numerous studies have attempted to identify markers that could facilitate the diagnosis and predict the course of GVHD. Among them, REG3α and ST2 currently show the greatest promise; however, comprehensive validation remains lacking. Although several new drugs have been approved for GVHD treatment in recent years and some modifications to GVHD prophylaxis have been adopted into clinical practice, further research are needed to validate biomarkers and explore new therapeutic targets, particularly in gastrointestinal GVHD. The review aims to summarize current research on GVHD biomarkers and emerging treatment targets, with a particular focus on gastrointestinal tract disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.